CytoSorbents Corp Regains $1 Nasdaq Bid-Price Compliance; MVLS Risk Remains

What Happened

• CytoSorbents Corporation (CTSO) filed an 8-K on Sept. 23, 2026 and issued a press release (Exhibit 99.1) announcing that Nasdaq’s Listing Qualifications Staff confirmed on Sept. 22, 2026 that the company has regained compliance with the Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)), which requires a minimum $1.00 per share bid price.
• The company remains noncompliant with Nasdaq’s market value of listed securities (MVLS) requirement (Nasdaq Listing Rule 5550(b)(2)). Nasdaq notified CytoSorbents of that deficiency on June 29, 2026 and gave a compliance period running through Dec. 28, 2026.

Key Details

• Nasdaq confirmed regained compliance with the $1.00 minimum bid price on Sept. 22, 2026.
• MVLS deficiency: market value must equal or exceed $35 million for at least 10 consecutive business days to regain compliance.
• Compliance deadline for the MVLS requirement: Dec. 28, 2026 (180-day period from the June 29, 2026 notice).
• Company may pursue options to regain compliance (monitor market value, or consider increasing stockholders’ equity to at least $2.5 million); failure to regain compliance could lead to delisting notification and an appeal process.

Why It Matters

• Regaining the $1.00 bid-price compliance removes an immediate listing risk tied to low share price, which is positive for liquidity and continued Nasdaq listing in the short term.
• The outstanding MVLS deficiency is a material risk: if the company’s market value does not reach the $35M threshold for the required period by Dec. 28, 2026, Nasdaq could begin delisting proceedings. Investors should watch market capitalization, share price trends, and any company actions (equity changes, strategic moves) intended to restore MVLS compliance.